Kane Biotech Showcases revyve™ Preclinical and Clinical Case Study Findings at North American Wound Care Conferences

Core Insights - Kane Biotech Inc. presented novel preclinical data and clinical case observations at major North American wound care conferences, showcasing the potential of its product revyve in wound care [1][2][3] Preclinical Data - In vitro studies demonstrated revyve's effectiveness in inhibiting key proteases, achieving over 80% reduction in matrix metalloproteinases (MMPs) activity, 82% reduction in elastase activity, and complete inhibition of collagenase and TACE [6][7] - Chronic wounds may exhibit TNF-α levels that exceed those in acute wounds by up to 100-fold, highlighting the need for effective treatments [2] Clinical Observations - Clinical case series indicated significant improvements in chronic wound patients using revyve, with clinically meaningful reductions in wound size and pain over a period of 6 to 12 weeks [6] - Specific cases reported include a 60% reduction in wound size over two months for a venous leg ulcer and complete pain elimination in a painful pressure wound [8] Conference Engagement - Kane Biotech engaged healthcare professionals at the NSWOCC and SAWC conferences, providing educational materials and product demonstrations of revyve [5][9] - The presentations aimed to reinforce the company's innovation in wound care and demonstrate the clinical value and commercial potential of revyve [9] Product Overview - Revyve is designed to address biofilms and wound bacteria, which are significant contributors to antibiotic resistance in wounds, potentially leading to serious clinical outcomes and high costs [9]